Simonelli Sara, Gianazza Elisabetta, Mombelli Giuliana, Bondioli Alighiero, Ferraro Giovanni, Penco Silvana, Sirtori Cesare R, Franceschini Guido, Calabresi Laura
Department of Pharmacological Sciences, Università degli Studi di Milano, 20133 Milano, Italy.
Arch Intern Med. 2012 Jan 23;172(2):179-81. doi: 10.1001/archinternmed.2011.661.
An antibody against the lecithin:cholesterol acyltransferase (LCAT) enzyme, which negates cholesterol esterification in plasma, causing severe high-density lipoprotein deficiency (HD), was identified in a woman with a large-cell non-Hodgkin lymphoma. Successful treatment of the lymphoma resulted in clearance of the antibody and complete correction of the defective cholesterol esterification and HD. To our knowledge, an acquired LCAT deficiency leading to severe HD has not been reported previously in association with a malignant disease, and this patient represents the first such documented case.
在一名患有大细胞非霍奇金淋巴瘤的女性患者体内，发现了一种针对卵磷脂胆固醇酰基转移酶（LCAT）的抗体，该抗体可消除血浆中的胆固醇酯化作用，导致严重的高密度脂蛋白缺乏（HD）。淋巴瘤的成功治疗使抗体清除，胆固醇酯化缺陷和HD得到完全纠正。据我们所知，先前尚未报道过与恶性疾病相关的导致严重HD的后天性LCAT缺乏症，该患者是首例有记录的此类病例。
